Vericel Corporation (VCEL)
NASDAQ:VCEL
Want to see VCEL full AI Analyst Report?
VCEL Stock Chart & Stats
$35.68
$1.36(2.35%)
At close: 4:00 PM EST
$35.68
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$28.95 - $45.97
Previous CloseN/A
Volume83.17K
Average Volume (3M)650.98K
Market Cap
$1.89B
Enterprise Value$1.69B
Total Cash (Recent Filing)$145.34M
Total Debt (Recent Filing)$94.42M
Price to Earnings (P/E)87.6
Beta0.92
Next Earnings
Aug 05, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding51,068,230
10 Day Avg. Volume549,984
30 Day Avg. Volume650,982
Financial Highlights & Ratios
PEG Ratio1.93
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue5.78
Enterprise Value/Gross Profit7.72
Enterprise Value/Ebitda50.61
Forecast
1Y Price Target
$61.00Price Target Upside70.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.47
Revenue Forecast (FY)$323.43M
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationVericel has shifted to consistent cash generation with operating cash flow above net income and materially improved free cash flow in the trailing period. This durable cash conversion funds reinvestment, funds clinical/commercial expansion, supports M&A or buybacks, and reduces external financing reliance.
High Gross Margins And Revenue TurnaroundThe business benefits from a high-margin, product-specific model (autologous implants and burn therapies) yielding ~75% gross margins. Combined with multi-year revenue growth and a move to sustained profitability, this margin profile creates durable operating leverage as volumes scale and drives cash generation.
Commercial Execution And Expanding Sales CoverageEvidence of successful field execution—expanded sales force delivering higher biopsies, implants and improved biopsy-to-implant pull-through—indicates scalable commercial capability. Durable commercial traction across surgeons and territories supports sustained procedure adoption and long-term revenue growth.
Bears Say
BARDA Revenue Timing UncertaintyWhile BARDA provides a meaningful structural pathway for NexoBrid scale, the bulk of value is contingent on optional procurements and development awards. Revenue timing and realization are uncertain, making BARDA a multi-year upside rather than a guaranteed near-term cash flow driver and complicating planning.
Reliance On Biopsy-to-implant ConversionMACI’s commercial model depends on converting biopsies to implants; reversal or stagnation in conversion rates would directly depress revenue and margin leverage. This operational dependency makes growth sensitive to surgeon behavior, scheduling, and patient follow-through—factors outside purely manufacturing control.
Margin Variability And Modest ROEDespite high gross margins, operating and net margins remain moderate due to reinvestment in sales, manufacturing and trials. ROE is mid-single-digit, indicating capital returns haven't fully recovered. Continued investment could keep near-term margin variability and delay stronger returns on equity.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $28.95 and its highest was $45.97 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $1.89B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 55 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on May 07, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.033.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is -0.03.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 51,068,230 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went down -4.486%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.00 (70.96% Upside)
$61.00 (70.96% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $327.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-15.49%
12-Months-Change
Fundamentals
Return on Equity
6.41%
Trailing 12-Months
Asset Growth
14.38%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$61.00
▲(70.96% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
32.87% Mutual Funds
37.73% Other Institutional Investors
4.40% Public Companies and
Individual Investors